Search

Your search keyword '"Kimbrell, Hillary"' showing total 28 results
Start Over Author "Kimbrell, Hillary"
28 results on '"Kimbrell, Hillary"'

1. Supplemental Figure 5 from Diagnostic Distinction of Malignant Melanoma and Benign Nevi by a Gene Expression Signature and Correlation to Clinical Outcomes

Author

Ko, Jennifer S., primary, Matharoo-Ball, Balwir, primary, Billings, Steven D., primary, Thomson, Brian J., primary, Tang, Jean Y., primary, Sarin, Kavita Y., primary, Cai, Emily, primary, Kim, Jinah, primary, Rock, Colleen, primary, Kimbrell, Hillary Z., primary, Flake, Darl D., primary, Warf, M. Bryan, primary, Nelson, Jonathan, primary, Davis, Thaylon, primary, Miller, Catherine, primary, Rushton, Kristen, primary, Hartman, Anne-Renee, primary, Wenstrup, Richard J., primary, and Clarke, Loren E., primary

Published
2023
Full Text
View/download PDF

2. Supplemental Figure 2 from Diagnostic Distinction of Malignant Melanoma and Benign Nevi by a Gene Expression Signature and Correlation to Clinical Outcomes

Author

Ko, Jennifer S., primary, Matharoo-Ball, Balwir, primary, Billings, Steven D., primary, Thomson, Brian J., primary, Tang, Jean Y., primary, Sarin, Kavita Y., primary, Cai, Emily, primary, Kim, Jinah, primary, Rock, Colleen, primary, Kimbrell, Hillary Z., primary, Flake, Darl D., primary, Warf, M. Bryan, primary, Nelson, Jonathan, primary, Davis, Thaylon, primary, Miller, Catherine, primary, Rushton, Kristen, primary, Hartman, Anne-Renee, primary, Wenstrup, Richard J., primary, and Clarke, Loren E., primary

Published
2023
Full Text
View/download PDF

3. Supplemental Figure 3 from Diagnostic Distinction of Malignant Melanoma and Benign Nevi by a Gene Expression Signature and Correlation to Clinical Outcomes

Author

Ko, Jennifer S., primary, Matharoo-Ball, Balwir, primary, Billings, Steven D., primary, Thomson, Brian J., primary, Tang, Jean Y., primary, Sarin, Kavita Y., primary, Cai, Emily, primary, Kim, Jinah, primary, Rock, Colleen, primary, Kimbrell, Hillary Z., primary, Flake, Darl D., primary, Warf, M. Bryan, primary, Nelson, Jonathan, primary, Davis, Thaylon, primary, Miller, Catherine, primary, Rushton, Kristen, primary, Hartman, Anne-Renee, primary, Wenstrup, Richard J., primary, and Clarke, Loren E., primary

Published
2023
Full Text
View/download PDF

4. Supplemental Figure 1 from Diagnostic Distinction of Malignant Melanoma and Benign Nevi by a Gene Expression Signature and Correlation to Clinical Outcomes

Author

Ko, Jennifer S., primary, Matharoo-Ball, Balwir, primary, Billings, Steven D., primary, Thomson, Brian J., primary, Tang, Jean Y., primary, Sarin, Kavita Y., primary, Cai, Emily, primary, Kim, Jinah, primary, Rock, Colleen, primary, Kimbrell, Hillary Z., primary, Flake, Darl D., primary, Warf, M. Bryan, primary, Nelson, Jonathan, primary, Davis, Thaylon, primary, Miller, Catherine, primary, Rushton, Kristen, primary, Hartman, Anne-Renee, primary, Wenstrup, Richard J., primary, and Clarke, Loren E., primary

Published
2023
Full Text
View/download PDF

5. Supplemental Figure 7 from Diagnostic Distinction of Malignant Melanoma and Benign Nevi by a Gene Expression Signature and Correlation to Clinical Outcomes

Author

Ko, Jennifer S., primary, Matharoo-Ball, Balwir, primary, Billings, Steven D., primary, Thomson, Brian J., primary, Tang, Jean Y., primary, Sarin, Kavita Y., primary, Cai, Emily, primary, Kim, Jinah, primary, Rock, Colleen, primary, Kimbrell, Hillary Z., primary, Flake, Darl D., primary, Warf, M. Bryan, primary, Nelson, Jonathan, primary, Davis, Thaylon, primary, Miller, Catherine, primary, Rushton, Kristen, primary, Hartman, Anne-Renee, primary, Wenstrup, Richard J., primary, and Clarke, Loren E., primary

Published
2023
Full Text
View/download PDF

6. Supplemental Figure 4 from Diagnostic Distinction of Malignant Melanoma and Benign Nevi by a Gene Expression Signature and Correlation to Clinical Outcomes

Author

Ko, Jennifer S., primary, Matharoo-Ball, Balwir, primary, Billings, Steven D., primary, Thomson, Brian J., primary, Tang, Jean Y., primary, Sarin, Kavita Y., primary, Cai, Emily, primary, Kim, Jinah, primary, Rock, Colleen, primary, Kimbrell, Hillary Z., primary, Flake, Darl D., primary, Warf, M. Bryan, primary, Nelson, Jonathan, primary, Davis, Thaylon, primary, Miller, Catherine, primary, Rushton, Kristen, primary, Hartman, Anne-Renee, primary, Wenstrup, Richard J., primary, and Clarke, Loren E., primary

Published
2023
Full Text
View/download PDF

7. Supplemental Figure 6 from Diagnostic Distinction of Malignant Melanoma and Benign Nevi by a Gene Expression Signature and Correlation to Clinical Outcomes

Author

Ko, Jennifer S., primary, Matharoo-Ball, Balwir, primary, Billings, Steven D., primary, Thomson, Brian J., primary, Tang, Jean Y., primary, Sarin, Kavita Y., primary, Cai, Emily, primary, Kim, Jinah, primary, Rock, Colleen, primary, Kimbrell, Hillary Z., primary, Flake, Darl D., primary, Warf, M. Bryan, primary, Nelson, Jonathan, primary, Davis, Thaylon, primary, Miller, Catherine, primary, Rushton, Kristen, primary, Hartman, Anne-Renee, primary, Wenstrup, Richard J., primary, and Clarke, Loren E., primary

Published
2023
Full Text
View/download PDF

8. An Independent Validation of a Gene Expression Signature to Differentiate Malignant Melanoma From Benign Melanocytic Nevi

Author

Clarke, Loren E., Flake, Darl D., II, Busam, Klaus, Cockerell, Clay, Helm, Klaus, McNiff, Jennifer, Reed, Jon, Tschen, Jaime, Kim, Jinah, Barnhill, Raymond, Elenitsas, Rosalie, Prieto, Victor G., Nelson, Jonathan, Kimbrell, Hillary, Kolquist, Kathryn A., Brown, Krystal L., Warf, Bryan M., Roa, Benjamin B., and Wenstrup, Richard J.

Published
2017
Full Text
View/download PDF

11. Diagnostic Distinction of Malignant Melanoma and Benign Nevi by a Gene Expression Signature and Correlation to Clinical Outcomes

Author

Ko, Jennifer S., primary, Matharoo-Ball, Balwir, additional, Billings, Steven D., additional, Thomson, Brian J., additional, Tang, Jean Y., additional, Sarin, Kavita Y., additional, Cai, Emily, additional, Kim, Jinah, additional, Rock, Colleen, additional, Kimbrell, Hillary Z., additional, Flake, Darl D., additional, Warf, M. Bryan, additional, Nelson, Jonathan, additional, Davis, Thaylon, additional, Miller, Catherine, additional, Rushton, Kristen, additional, Hartman, Anne-Renee, additional, Wenstrup, Richard J., additional, and Clarke, Loren E., additional

Published
2017
Full Text
View/download PDF

13. Mixed Large Cell Neuroendocrine Carcinoma and Adenocarcinoma with Spindle Cell and Clear Cell Features in the Extrahepatic Bile Duct

Author

Wysocki, John, Agarwal, Rishi, Bratton, Laura, Nguyen, Jeremy, Weidenhaft, Mandy Crause, Shores, Nathan, and Kimbrell, Hillary Z.

Subjects
Article Subject
Abstract

Mixed adenoneuroendocrine carcinomas, spindle cell carcinomas, and clear cell carcinomas are all rare tumors in the biliary tract. We present the first case, to our knowledge, of an extrahepatic bile duct carcinoma composed of all three types. A 65-year-old man with prior cholecystectomy presented with painless jaundice, vomiting, and weight loss. CA19-9 and alpha-fetoprotein (AFP) were elevated. Cholangioscopy revealed a friable mass extending from the middle of the common bile duct to the common hepatic duct. A bile duct excision was performed. Gross examination revealed a 3.6 cm intraluminal polypoid tumor. Microscopically, the tumor had foci of conventional adenocarcinoma (CK7-positive and CA19-9-postive) surrounded by malignant-appearing spindle cells that were positive for cytokeratins and vimentin. Additionally, there were separate areas of large cell neuroendocrine carcinoma (LCNEC). Foci of clear cell carcinoma merged into both the LCNEC and the adenocarcinoma. Tumor invaded through the bile duct wall with extensive perineural and vascular invasion. Circumferential margins were positive. The patient’s poor performance status precluded adjuvant therapy and he died with recurrent and metastatic disease 5 months after surgery. This is consistent with the reported poor survival rates of biliary mixed adenoneuroendocrine carcinomas.

Published
2014
Full Text
View/download PDF

14. An independent validation of a gene expression signature to differentiate malignant melanoma from benign melanocytic nevi

Author

Clarke, Loren E., primary, Flake, Darl D., additional, Busam, Klaus, additional, Cockerell, Clay, additional, Helm, Klaus, additional, McNiff, Jennifer, additional, Reed, Jon, additional, Tschen, Jaime, additional, Kim, Jinah, additional, Barnhill, Raymond, additional, Elenitsas, Rosalie, additional, Prieto, Victor G., additional, Nelson, Jonathan, additional, Kimbrell, Hillary, additional, Kolquist, Kathryn A., additional, Brown, Krystal L., additional, Warf, M. Bryan, additional, Roa, Benjamin B., additional, and Wenstrup, Richard J., additional

Published
2016
Full Text
View/download PDF

15. Gigapixel surface imaging of radical prostatectomy specimens for comprehensive detection of cancer-positive surgical margins using structured illumination microscopy

Author

Wang, Mei, primary, Tulman, David B., additional, Sholl, Andrew B., additional, Kimbrell, Hillary Z., additional, Mandava, Sree H., additional, Elfer, Katherine N., additional, Luethy, Samuel, additional, Maddox, Michael M., additional, Lai, Weil, additional, Lee, Benjamin R., additional, and Brown, J. Quincy, additional

Published
2016
Full Text
View/download PDF

19. BRAFTesting in Multifocal Papillary Thyroid Carcinoma

Author

Kimbrell, Hillary Z., primary, Sholl, Andrew B., additional, Ratnayaka, Swarnamala, additional, Japa, Shanker, additional, Lacey, Michelle, additional, Carpio, Gandahari, additional, Bhatia, Parisha, additional, and Kandil, Emad, additional

Published
2015
Full Text
View/download PDF

22. The Effect of Age, Race, Pregnancy and Treatment Facility on the Follow-up Biopsy Rate for Atypical Squamous Cells, Cannot Exclude High-grade Squamous Intraepithelial Lesion (ASC-H) and High-grade Squamous Intraepithelial Lesion (HSIL) Diagnoses at Two New Orleans Teaching Hospitals

Author

Gill, Farrukh, primary, Hirsh, Sharon, additional, Kimbrell, Hillary, additional, Lacey, Michelle, additional, Goswami, Monica, additional, and Moroz, Krzysztof, additional

Published
2012
Full Text
View/download PDF

24. High-Resolution Rapid Diagnostic Imaging of Whole Prostate Biopsies Using Video-Rate Fluorescence Structured Illumination Microscopy.

Author

Mei Wang, Kimbrell, Hillary Z., Sholl, Andrew B., Tulman, David B., Elfer, Katherine N., Schlichenmeyer, Tyler C., Lee, Benjamin R., Lacey, Michelle, and Quincy Brown, J.

Subjects
*PROSTATE tumors, *PROSTATE surgery, *BIOPSY, *FLUORESCENCE microscopy, *HIGH resolution imaging, *DIAGNOSIS
Abstract

Rapid assessment of prostate core biopsy pathology at the point-of-procedure could provide benefit in a variety of clinical situations. Even with advanced transrectal ultrasound guidance and saturation biopsy protocols, prostate cancer can be missed in up to half of all initial biopsy procedures. In addition, collection of tumor specimens for downstream histologic, molecular, and genetic analysis is hindered by low tumor yield due to inability to identify prostate cancer grossly. However, current point-of-procedure pathology protocols, such as frozen section analysis (FSA), are destructive and too time- and labor-intensive to be practical or economical. Ex vivo microscopy of the excised specimens, stained with fast-acting fluorescent histology dyes, could be an attractive nondestructive alternative to FSA. In this work, we report the first demonstration of video-rate structured illumination microscopy (VR-SIM) for rapid high-resolution diagnostic imaging of prostate biopsies in realistic point-ofprocedure timeframes. Large mosaic images of prostate biopsies stained with acridine orange are rendered in seconds and contain excellent contrast and detail, exhibiting close correlation with corresponding hematoxylin and eosin histology. A clinically relevant review of VR-SIM images of 34 unfixed and uncut prostate core biopsies by two independent pathologists resulted in an area under the receiver operative curve (AUC) of 0.82-0.88, with a sensitivity ranging from 63% to 88% and a specificity ranging from 78% to 89%. When biopsies contained more than 5% tumor content, the sensitivity improved to 75% to 92%. The image quality, speed, minimal complexity, and ease of use of VR-SIM could prove to be features in favor of adoption as an alternative to destructive pathology at the point-of-procedure. [ABSTRACT FROM AUTHOR]

Published
2015
Full Text
View/download PDF

25. BRAF Testing in Multifocal Papillary Thyroid Carcinoma.

Author

Kimbrell, Hillary Z., Sholl, Andrew B., Ratnayaka, Swarnamala, Japa, Shanker, Lacey, Michelle, Carpio, Gandahari, Bhatia, Parisha, and Kandil, Emad

Subjects
*BRAF genes, *PAPILLARY carcinoma, *THYROID cancer, *GENETIC mutation, *POLYMERASE chain reaction, *TUMORS, *FORMALDEHYDE
Abstract

Background. BRAF V600E mutation is associated with poor prognosis in patients with papillary thyroid carcinoma (PTC). PTC is often multifocal, and there are no guidelines on how many tumors to test for BRAF mutation in multifocal PTC. Methods. Fifty-seven separate formalin-fixed and paraffin-embedded PTCs from twenty-seven patients were manually macrodissected and tested for BRAF mutation using a commercial allele-specific real-time polymerase chain reaction-based assay (Entrogen, Woodland Hills, CA). Data related to histologic characteristics, patient demographics, and clinical outcomes were collected. Results. All mutations detected were BRAF V600E. Seventeen patients (63%) had concordant mutation status in the largest and second-largest tumors (i.e., both were positive or both were negative). The remaining ten patients (37%) had discordant mutation status. Six of the patients with discordant tumors (22% overall) had a BRAF-negative largest tumor and a BRAF-positive second-largest tumor. No histologic feature was found to help predict which cases would be discordant. Conclusions. Patients with multifocal PTC whose largest tumor is BRAF-negative can have smaller tumors that are BRAF-positive. Therefore, molecular testing of more than just the dominant tumor should be considered. Future studies are warranted to establish whether finding a BRAF mutation in a smaller tumor has clinical significance. [ABSTRACT FROM AUTHOR]

Published
2015
Full Text
View/download PDF

28. Antemortem Diagnosis of Likely Giant Cell Carcinoma of the Lung by Pleural Fluid Cytology Evaluation.

Author

Oncale M, Kimbrell HZ, and Barnhill M

Abstract

Background: Sarcomatoid carcinomas (SCs) are poorly differentiated non-small cell lung carcinomas containing components of either sarcomatoid differentiation or true sarcoma. SCs have a poor prognosis; some studies suggest a 6-month survival rate <27%., Case Report: We present a case of the rare entity of SC, likely giant cell carcinoma, that is unique because our patient was older than the mean age at presentation, was female, and had a central lesion., Conclusion: Clinicians need to be aware of the histologic entities of SCs of the lung because of the aggressive nature of these lesions and because of the need for further studies to determine possible treatment regimens.

Published
2015

Catalog

Books, media, physical & digital resources
See catalog results